ACIU · AC Immune SA
Market Cap
$282.37M
Shares
99.43M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.84
Open$2.70
Day$2.70–2.87
52W close$2.12–3.99
Avg vol 30d215K
Short int3.4M · 3.4% float · 14.3d
Short vol66%
DataJan 2020–Sep 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
+31.4%
Trailing year
Short interest
3.4%
Latest settlement · 14.3 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Buy
Momentum
Weak
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 15.2 · calm
Equity put/call 0.56
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+0%
above
Price vs 50-day avg
+15%
above
RSI (14)
62
neutral
MACD trend
Positive
52-week position
39%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+24%
trailing
6-month return
−5%
trailing
YTD return
−10%
this year
Relative strength
−20%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow
Distributing
-9% holders QoQ · +6 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
3.43% of float · ▼ -4.1% MoM · 14.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
43 holders — mid 3-yr range
Squeeze score
62
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
77%
annualized · 1-yr
Max drawdown
−47%
past year
ATR
5.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+0%
Bullish
Price vs 50-day avg
+15%
Bullish
RSI (14)
62
Neutral
MACD trend
Positive
Bullish
52-week position
39%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow
Distributing
-9% holders QoQ · +6 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
3.43% of float · ▼ -4.1% MoM · 14.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
43 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2
Now $3 · 39%
Range high $4
vs 200-day avg +0%
vs 50-day avg +15%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ACIU
this stock
AC Immune SA
|
$282.37M | -9.6% | — | — | 3.4% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$140.51B | +22.8% | +46.2% | 32.3 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$84.82B | +10.4% | +20.8% | 20.4 | 2.3% |
|
ARGX
Argenx SE
|
$65.63B | +25.5% | — | — | 1.9% |
|
MRNA
Moderna, Inc.
|
$61.59B | +411.4% | +4.3% | — | 13.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ACIU | -0.4% | +24.0% | -5.3% | +7.6% | -9.6% |
| SPY | -0.1% | -0.6% | +14.9% | -0.3% | +12.2% |
| vs SPY | -0.2% | +24.6% | -20.2% | +7.8% | -21.8% |
Key facts
CIK
1651625
CUSIP
H00263105
13F (30d)
36 filings
36 filers
Visit website
Investor relations